Groningen 2015

INTERNATIONAL SYMPOSIUM ON DUPUYTREN DISEASE

This conference was organized by the International Dupuytren Society, hosted by the University Medical Center Groningen UMCG and supported by the Federation of European Societies for Surgery of the Hand FESSH and the International Federation of Societies for Surgery of the Hand IFSSH. The conference included academic research presentations and panel discussions regarding Dupuytren disease and related conditions. The goal of the conference has beenraising awareness regarding Dupuytren disease, sharing new concepts and ideas, and promoting cooperative efforts to work for a cure.

The symposium was a gathering of researchers and clinicians with a wide spectrum of interests: cell biology, genomics, surgery, pharmacotherapy, radiotherapy, biomechanics, therapy, as they relate to Dupuytren disease and related conditions. The conference was held at

22 / 23 May 2015, Groningen, The Netherlands

Accredited by EACCME for 12 CME points. Accredited by the Nederlandse Orthopaedische Vereniging (NOV)
and the Nederlandse Vereniging voor Plastische Chirurgie (NVPC) for 16 points.

The Groningen conference followed the symposium held in May 2010 in Miami, Florida (Conference History). Results of that conference have been published in Charles Eaton, Heinrich Seegenschmiedt, Ardheshir Bayat, Giulio Gabbiani, Paul Werker, and Wolfgang Wach (Eds.) “Dupuytren’s Disease and Related Hyperproliferative Disorders” Springer, 2012 ebook.

The proccedings of the Groningen conference have been published as book by Springer in 2016  proceedings.

International Conference on Dupuytren Disease and Related Diseases

Groningen, The Netherlands

22 / 23 May 2015

 

    

Scientific Program

Note that the proceedings of this conference will be published by Springer as a book (printed and ebook) and will probably appear in June/July 2016.

Conference Program as PDF

Abstracts of presentations on Friday (including posters): abstracts_Friday

Abstracts of presentations on Saturday: abstracts_Saturday

Day 1  Friday, 22 May 2015

08:30 Paul Werker Opening the conference
08:35 Jos Aartsen Welcome from the CEO of UMCG
08:40 Wolfgang Wach & Charles Eaton Welcome from the International Dupuytren Society & the Dupuytren Foundation video
Session 1 Epidemiology and Patients’ Views B. Reichert, Z. Szabo
08:45 Zsolt Szabo Lecture : Treatment of Dupuytren in different countries and the role of FESSH and IFSSH in promoting knowledge for hand surgeons video
09:05 Joseph Dias The epidemiology of surgical intervention for Dupuytren Contracture in England video
09:11 Bert Reichert Favorite Options of German Hand Surgeons in the Treatment of Dupuytren Disease video
09:17 Philip Blazar Trends in Dupuytren’s Treatment in the United States video
09:23 Discussion
09:38 Wolfgang Wach The Patient’s View and Needs – An International Survey: Dupuytren Disease video
09:44 Hester Kan Patients’ preferences for treatment for Dupuytren disease: a Discrete Choice Experiment
09:50 Discussion
Session 2 Cellular and Extracellular Events
R. Bank, B. Hinz
10:30 David O’Gorman Lecture : The extra­cellular matrix in Dupuytren disease video
10:50 Marianna Kruithof‐de Julio PDGFR-β targeted modified interferon gamma in Dupuytren disease
10:56 Marike van Beuge Wnt pathway in Dupuytren disease, connecting pro-fibrotic signals video
11:02 Ian Clark Biomarkers of post-surgical outcome in Dupuytren disease video
11:08 Jagdeep Nanchahal Tumour necrosis factor (TNF) as a therapeutic target in Dupuytren disease video
11:14 Discussion
11:30 David O’Gorman (chair) Controversies 1: Pathogenesis of Dupuytren Disease: active or passive contracture?
11:32 Jagdeep Nanchahal Active Contracture video
11:37 Charles Eaton Passive Contracture video
Session 3 Genetics and Associations
H. Hennies, R. Ophoff
13:00 Roel Ophoff Lecture : Genetics in Dupuytren Disease
13:20 Michael Ng A Large European Genome-wide Association Study Reveals Multiple New Genetic Susceptibility Variants for Dupuytren Disease video
13:26 Kerstin Becker Meta-analysis of genome-wide imputed GWAS identifies new significant loci in patients with Dupuytren´s disease
13:32 Juanjiangmeng Du Identification and characterization of functional genetic variants in Dupuytren Disease
13:38 Discussion
13:53 Dieuwke Broekstra A systematic review and meta-analysis on the association between Dupuytren disease and diabetes video
13:59 Dieuwke Broekstra The association between vibration and Dupuytren disease: a comparison between elderly field hockey players and controls video
14:05 Discussion
14:15 Ilse Degreef (chair) Controversies 2: The benefit of splinting for Dupuytren contracture
14:17 Adrian Chojnowski Splinting confers no benefit video
14:22 Wolfgang Wach Splinting is beneficial video
Session 4 Collagenase Injection
S Coleman,S Wilbrand
15:15 Larry Hurst Lecture : Collagenase Treatment – Journey from Bench to Current Advanced Clinical Use
15:35 Paul Werker Dupuytren Disease in the thumb and first webspace and collagenase treatment video
15:41 Jesper Nordenskjöld Efficacy of using local anesthesia before collagenase injection in reducing overall pain experience in patients treated for Dupuytren’s contracture: A quasi-randomized study video
15:47 Gary M. Pess Effect of Delayed Finger Extension on the Efficacy and Safety of Collagenase Clostridium Histolyticum Treatment for Dupuytren Contracture video
15:51 Massimo Corain The use of a dynamic dorsal splint for Dupuytren Rehabilitation after collagenase cancelled
15:57 Discussion
16:19 International Dupuytren Society Dupuytren Award 2014 to Clayton Peimer
16:24 Clayton Peimer Treatment with Collagenase Clostridium Histolyticum: Five-Year CORDLESS Data video
16:30 Marie Badalamente Prospective Multicenter, Multinational Study to Evaluate the Safety and Efficacy of Concurrent Collagenase Clostridium Histolyticum Injections to Treat Two Dupuytren Contractures in the Same Hand video
16:36 Marie Badalamente An Open-label, Controlled Phase 2a Study of the Safety and Efficacy of Injectable Collagenase Clostridium Histolyticum (CCH) in Patients with Adhesive Capsulitis (Frozen Shoulder) video
16:42 David Warwick Collagenase : what we may never know – a discussion paper video
16:48 Discussion
17:04 Charles Eaton (chair) Controversies 3: The best minimally invasive treatment for Dupuytren Disease:PNF or Collagenase?
17:06 Paul Werker Percutaneous Needle Fasciotomy video
17:11 David Warwick Collagenase video
Day 2  Saturday, 23 May 2015
Session 5 Assessment / Percutaneous Needle Fasciotomy
U. Lanz, G. Pess
08:30 Joseph Dias MCID for the Patient Evaluation Measure as a Patient Rated Outcome Measure for Dupuytren Contracture video
08:36 Chao Zhou Predictors of Satisfaction with Hand Function in Patients with Dupuytren Disease video
08:42 Joseph Dias URAMS as a PROM for Dupuytren Contracture Patients video
08:48 Discussion
09:03 Gary Pess Tips and Pearls for Percutaneous Needle Fasciotomy and Collagenase – A Ten Year Personal Experience video
09:09 Margot Vlot Percutaneous Needle Fasciotomy for secondary or higher recurrence in Dupuytren disease video
09:15 Steven Hovius Extensive Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy in Patients with Primary Dupuytren Contracture; a Randomized Controlled Trial video
09:21 Discussion
09:37 Joseph Dias (chair) Controversies 4: How to treat severe PIP contractures: minimally invasive or surgically?
09:41 Clayton Peimer Minimally invasive methods
09:46 Caroline Leclercq Surgical correction video
Session 6 Comparative Studies / Recurrence
C. Leclercq, D. Elliot
10:45 David Elliot Lecture : Treatment of Dupuytren Disease – Where are we now?
11:05 Paul Binhammer Steroid injection and needle aponeurotomy for Dupuytren disease: long-term follow-up of a randomized controlled trial video
11:11 Eva-Maria Baur Minimally invasive treatment of Dupuytren:
Collagenase vs. PNF
video
11:17 Chao Zhou Collagenase Clostridium Histolyticum versus Partial Fasciectomy for Dupuytren’s contracture: Early Outcomes From A Multicenter Propensity-Score Matched Study video
11:23 Discussion
11:35 Jane C Messina Actual Indications of Continuous Extension Technique (TEC) for Severe Dupuytren Disease video
11:41 Atanu Biswas Preliminary soft-tissue distraction versus checkrein ligament release after fasciectomy in the treatment of Dupuytren proximal interphalangeal joint contractures video
11:47 Discussion
11:55 Rinze Zwanenburg The Palmodigital Spiralling Sheath
12:01 Rosanne Lanting Clusters in short term disease course in participants with primary Dupuytren Disease
12:07 Discussion
12:15 Ruud Selles Recurrence after Treatment for Dupuytren Disease; A consensus-based definition video
12:21 Caroline Leclercq Recurrence after Dupuytren’s disease:the time factor
12:27 Ilse Degreef Is Recurrence of Dupuytren Disease Prevented by Full-Thickness Grafting Surgery? video
12:33 Discussion
Session 7 Related disease & Other Treatments
R. Selles, R. Shaffer
13:50 Heinrich Seegenschmiedt Lecture : Radiotherapy for Early Stage
Dupuytren and Ledderhose Disease
video
14:10 Catherine Ball A Systematic Review Of Non-Surgical Treatments for Early Dupuytren Disease video
14:16 Gary Manley The Patient’s View and Needs – An International Survey: Ledderhose Disease video
14:22 Discussion
14:32 Gloria Sue Use of Acellular Dermal Matrix in Dupuytren Disease video
14:38 Ilse Degreef In vivo RCT Tension versus compression on Dupuytren video
14:44 Discussion
14:54 Mels van Driel Lecture : Peyronie’s Disease Treatment:
The State of the Art
video
Symposia Focus on Research
J. Dias
15:35 Joseph Dias Introduction to the symposia video
15:40 David O’Gorman Basic Research: important prerequisites for future studies D. O’Gorman video
Ruud Bank We need better methodologies for Dupuytren research video
Dominic Furniss Requirements for genetic research and novel ways to attract funding video
16:30 Maria Badalamente Clinical Research: international collaboration to execute high powered clinical trials M. Badalamente video
Joseph Dias Patient Rated Outcome Measures (PROMS) video
Charles Eaton International Dupuytren Data Bank (IDDB) video
Steve Coleman Clinical Research in Australia video
17:20 Paul Werker Closing remarks